All articles tagged with #weightloss
A health transformation story in which a person reportedly shed 190 pounds and reversed fatty liver disease by following a three-step plan, highlighting the link between significant weight loss and improved liver health.
Retatrutide is an experimental peptide that may drive substantial weight loss by modulating appetite and metabolism, but it is not approved anywhere, carries gastrointestinal and mood-related risks, and unregulated online access raises safety concerns; achieving a shredded appearance still depends on resistance training and a protein-rich diet under medical supervision.
Stanford researchers report that BRP, a 12‑amino‑acid peptide discovered via AI, suppresses appetite by acting on the hypothalamus, leading to reduced food intake and fat loss in animals with no major side effects, potentially offering a more targeted obesity treatment than Ozempic; human trials are planned after animal safety and efficacy are demonstrated.
A Cleveland Clinic study of nearly 8,000 adults who stopped GLP-1 medications (such as Ozempic or tirzepatide) found only modest weight regain after one year (average 0.5%), suggesting real-world outcomes may diverge from clinical trials. Many patients either stay on some form of obesity treatment or switch to alternatives, with weight loss largely maintained when ongoing care and lifestyle support are in place, though results vary across populations and settings.
Reports of scurvy linked to GLP-1 weight‑loss drugs have risen as these medications curb appetite and food intake, potentially causing vitamin C and other nutrient deficiencies. Experts note that malnutrition risk increases when appetite suppression leads to reduced consumption, and advise nutritional status assessment, meal planning with a dietitian, and targeted supplementation (e.g., vitamin C 100–200 mg) to prevent scurvy and other deficiencies while continuing GLP-1 therapy. Scurvy is reversible with proper supplementation and dietary adjustments.
Novo Nordisk’s stock fell about 15% after its weight‑loss candidate CagriSema failed to demonstrate non‑inferiority to Eli Lilly’s tirzepatide over 84 weeks (23% weight loss on CagriSema vs 25.5% for tirzepatide at 84 weeks). Lilly’s drug remains dominant in the market, and Novo is pursuing higher‑dose trials while facing competition, U.S. price pressure, and looming loss of exclusivity for Wegovy and Ozempic. The stock traded at its lowest since June 2021, and Lilly stock rose in premarket trading as Novo cautioned about slower growth in 2026.
A small randomized crossover trial in adults with overweight/obesity found that eating 45% of daily calories at a large breakfast and 20% at dinner led to weight loss over 28 days, with two plan variants—high-protein (less hungry) and high-fiber (slightly more weight loss and greater gut microbiome diversity). The high-fiber group lost about 4.87 kg and the high-protein group about 3.87 kg; both improved blood pressure and lipids. Limitations include a small, mostly male sample and short duration, so longer, larger studies are needed, with personalization and consideration of circadian factors.
A review of research indicates that individuals who stop using GLP-1 drugs like Ozempic and Wegovy for weight loss tend to regain their lost weight within approximately 18 months, and this regain occurs faster than with behavioral methods like dieting or exercise. To maintain health benefits after discontinuing these medications, lasting lifestyle changes are essential.
Doctors warn that weight-loss drugs like Ozempic and Wegovy, originally for diabetes, carry risks such as side effects and potential weight regain after stopping, emphasizing the importance of lifestyle changes and caution against viewing these medications as quick fixes.
Strategic fasting, a mindful and structured eating pattern, may be an effective way to lose belly fat by improving how the body stores and uses energy, offering an alternative to simply exercising more or reducing calories.
Many users of GLP-1 drugs like Ozempic struggle to stop using them due to intense hunger and weight regain, suggesting a potential lifelong dependency. While some, like Ellen Ogley, maintain weight loss through lifestyle changes, others experience significant weight regain, highlighting the importance of healthy habits during treatment. Experts recommend developing an exit strategy that includes lifestyle modifications to sustain weight loss after discontinuing the medication.
Eli Lilly's oral GLP-1 receptor agonist, orforglipron, successfully maintained weight loss in a Phase 3 trial after patients switched from injectable therapies, leading Lilly to submit it for FDA approval as a treatment for obesity.
Eli Lilly's new obesity pill helps patients maintain weight loss after switching from injections like Wegovy and Zepbound, with promising trial results suggesting it could serve as a needle-free long-term treatment option, potentially capturing significant market share in the growing weight loss drug industry.
The WHO highlights the potential of weight loss drugs like Mounjaro as a significant breakthrough in treating obesity, emphasizing the need for increased access, affordability, and comprehensive support, while noting these medications are not a standalone solution and should be part of broader lifestyle changes.
Researchers in China have developed fat-blocking microbeads made from green tea, vitamin E, and seaweed that showed promising results in rats fed a high-fat diet, suggesting a potential noninvasive dietary strategy for weight loss. Human trials are underway to confirm safety and effectiveness, and the microbeads could serve as an alternative to drugs and surgery for obesity management.